Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 2
2010 1
2011 2
2012 3
2013 2
2014 10
2015 8
2016 2
2019 2
2020 3
2021 4
2022 5
2023 9
2024 10
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A, Bernabe R, Buchmeier EL, Chang JW, Shiraishi Y, Sezgin Goksu S, Badzio A, Shi A, Daniel DB, Hoa NTT, Zemanova M, Mann H, Gowda H, Jiang H, Senan S; ADRIATIC Investigators. Cheng Y, et al. N Engl J Med. 2024 Oct 10;391(14):1313-1327. doi: 10.1056/NEJMoa2404873. Epub 2024 Sep 13. N Engl J Med. 2024. PMID: 39268857 Clinical Trial.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yañez E, Gümüş M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ; KEYNOTE-826 Investigators. Colombo N, et al. N Engl J Med. 2021 Nov 11;385(20):1856-1867. doi: 10.1056/NEJMoa2112435. Epub 2021 Sep 18. N Engl J Med. 2021. PMID: 34534429 Clinical Trial.
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.
Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, Zamagni C, Cui J, Cazzaniga M, Cil T, Jerzak KJ, Fuentes C, Yoshinami T, Rodriguez-Lescure A, Sezer A, Fontana A, Guarneri V, Molckovsky A, Mouret-Reynier MA, Demirci U, Zhang Y, Valota O, Lu DR, Martignoni M, Parameswaran J, Zhi X, Hamilton EP; VERITAC-2 Study Group. Campone M, et al. N Engl J Med. 2025 Aug 7;393(6):556-568. doi: 10.1056/NEJMoa2505725. Epub 2025 May 31. N Engl J Med. 2025. PMID: 40454645 Clinical Trial.
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.
Verlingue L, Italiano A, Prenen H, Guerra Alia EM, Tosi D, Perets R, Lugowska I, Moiseyenko V, Gumus M, Arslan C, Lindsay CR, Deva S, Taus Á, Oaknin A, Rottey S, Cicin I, Goksu SS, Smolin A, Roselló-Keränen S, Habigt C, Marbach D, Boetsch C, Dejardin D, Sleiman N, Evers S, Richard M, Ardeshir C, Charo J, Kraxner A, Teichgräber V, Keshelava N, Dziadziuszko R. Verlingue L, et al. Among authors: goksu ss. EBioMedicine. 2024 Nov;109:105374. doi: 10.1016/j.ebiom.2024.105374. Epub 2024 Oct 11. EBioMedicine. 2024. PMID: 39395231 Free PMC article. Clinical Trial.
The importance microRNAs as a biomarker in lung cancer.
Canatan D, Sonmez Y, Yılmaz O, Coşkun HŞ, Göksu SS, Uçar S, Aktekin MR. Canatan D, et al. Among authors: goksu ss. Acta Biomed. 2023 Feb 13;94(1):e2023045. doi: 10.23750/abm.v94i1.13334. Acta Biomed. 2023. PMID: 36786270 Free PMC article.
Major and minor salivary gland cancers: A multicenter retrospective study.
Hacioglu MB, Erdogan B, Bardakcı M, Algın E, Gulbagcı B, Hacibekiroglu I, Hamdard J, Olmez OF, Akkus H, Oksuzoglu B, Goksu SS, Dae SA, Sumbul AT, Ugraklı M, Karaagac M, Sahin E, Cabuk D, Ozer O, Yavuzsen T, Arıkan R, Köstek O, Atcı MM, Sakin A, Deligonul A, Bayır D, Dincer M, Unsal O, Yazıcı O, Zeynelgil E, Gulmez A, Harputluoglu H, Erol C, Sendur MAN, Aytekin A, Akagunduz B, Oner I, Er O, Oztosun B, Gumus M, Selçukbiricik F, Aykan MB, Karadurmus N, Degerli E, Demirci NS, Turkmen E, Şakalar T, Secmeler S, Tanrıverdi O, Alkan A, Kemal Y, Cil I, Unal C, Iriagaç Y, Alan O, Balli S, Urun Y, Ozcan E, Turhal NS, Cicin I. Hacioglu MB, et al. Among authors: goksu ss. Head Neck. 2023 Jul;45(7):1643-1653. doi: 10.1002/hed.27376. Epub 2023 Apr 21. Head Neck. 2023. PMID: 37084179
Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma.
Kuzu OF, Bolek H, Sertesen Camoz E, Karakas H, Sekmek S, Sim S, Isık S, Günaltılı M, Akkus AF, Tural D, Arslan C, Goksu SS, Sever ON, Karacin C, Sendur MAN, Karadurmus N, Yekedüz E, Ürün Y. Kuzu OF, et al. Among authors: goksu ss. BMC Cancer. 2025 Jul 25;25(1):1220. doi: 10.1186/s12885-025-14654-3. BMC Cancer. 2025. PMID: 40713516 Free PMC article.
Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group.
Şahin G, Tüzün EK, Güzel HG, Guliyev M, Dişli AK, Yazıcı M, Yıldız O, Güneş TK, Alkan S, Kahraman EG, Özel GS, İçli MC, Şahin E, Muğlu H, Acar C, Tunbekici S, Yüksel HÇ, Yücel H, Kahya BU, Kitaplı S, Büyükşimşek M, İpek ŞA, Dama PE, Usta EA, Yılmaz M, Aşık E, Özalp FR, Savsar MG, Kocaaslan E, Sim S, Ağaoğlu AB, Çamöz ES, Demir T, Uyar GC, Yıldırım A, Çınkır HY, Salim DK, Doğu GG, Alan Ö, Bayram E, Karaçin C, Güç ZG, Ekinci F, Eryılmaz MK, Semiz HS, Ünal OÜ, Göksu SS, Öztürk B, İnanç M, Uygun K, Hacıbekiroğlu İ, Erçolak V, Kara İO, Yazıcı O, Bilici A, Tanrıverdi Ö, Karaca B, Erman M, Gökmen E, Göker E, Yıldırım HÇ. Şahin G, et al. Among authors: goksu ss. Int J Cancer. 2025 Sep 19. doi: 10.1002/ijc.70165. Online ahead of print. Int J Cancer. 2025. PMID: 40968962
65 results